U-0521 is the inhibitor of the catechol-O-methyltransferase (COMT). U-0521 has the potential for the research of Parkinson’s disease[1].
U-0521 inhibits RBC COMT activity in a dose-dependent manner with an IC50 of 6 x10-6 M[1].
U-0521 (i.p.; 0-250 mg/kg; 10 min) inhibits COMT activity in a dose-dependent manner. 50% inhibition of enzyme activity is obtained at 90 mg/kg and maximum inhibition of 90% is obtained at 250 mg/kg[1].
[1]. Reches A, et al. Effect of 3’,4’-dihydroxy-2-methyl-propriophenone (U-0521) on catechol-O-methyltransferase activity and on DOPA accumulation in rat red blood cells and corpus striatum. Biochem Pharmacol. 1982;31(21):3415-3418.